Bruce Leuchter, CEO, Neurvati, explains why aligning drug development with patient-reported outcomes is key to demonstrating value and achieving payer alignment in the rare disease space.

A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, ...

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

In the first part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan ...

Bruce Leuchter, CEO, Neurvati, discusses why patient engagement is essential to understanding rare diseases and driving the ...

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts ...

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

In the third part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, describes ...

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical ...